The "Ocular Melanoma - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of ocular melanoma, historical and ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.

Syncona Ltd (”Syncona”), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, today issues its quarterly update covering the period ...

Piper Sandler lowered shares of Turnstone Biologics (NASDAQ:TSBX – Free Report) from an overweight rating to a neutral rating in a research report released on Wednesday, Marketbeat.com reports. The ...

The company is also carrying out a pair of phase 3 trials in cutaneous melanoma – PRISM-MEL-301 and TEBE-AM – and is due to start a third in adjuvant uveal melanoma (ATOM) before year-end.

Do you have blue eyes? We talked to experts to discover curious facts about baby blues, including whether your biological ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...